GlassScriptPhysician profile
Michael Winniford
NPI 1083647879
$2,576.71
in general payments reported to CMS, 2019-2025
24 companies · $451 in 2025
The $451 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $143 · 2021: $164 · 2022: $108 · 2023: $260 · 2024: $153 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $413.56 | 2019-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $334.64 | 2019-2023 | |
| Philips North America LLC | $284.02 | 2024-2025 | Lm Undivided, (Bh4) Igt Devices Undivided, (Am5) Lead Management |
| Irhythm Technologies, INC. | $269.55 | 2019-2023 | Zio Xt Patch |
| Boston Scientific Corporation | $165.09 | 2025 | Watchman Access System, Ingevity Mri |
| Pfizer INC. | $140.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $139.77 | 2019 | |
| Chiesi USA, INC. | $111.48 | 2025 | Kengreal |
| Astellas Pharma US INC | $99.96 | 2019 | |
| Amgen INC. | $94.22 | 2019 | |
| Abbott Laboratories | $91.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $78.35 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $75.04 | 2019-2023 | Camzyos |
| Braemar Manufacturing, LLC | $72.80 | 2019 | |
| Gilead Sciences, INC. | $46.79 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.39 | 2025 | Jardiance |
| Ge Healthcare | $23.10 | 2019 | |
| United Therapeutics Corporation | $20.61 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $17.33 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.76 | 2023 | |
| Vifor Pharma, INC. | $15.38 | 2019 | |
| Merck Sharp & Dohme LLC | $13.88 | 2025 | Verquvo |
| Akcea Therapeutics, INC. | $13.24 | 2019 | |
| Lantheus Medical Imaging, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Winniford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.